HDR Gateway logo
HDR Gateway logo

Bookmarks

Secure eResearch Platform (SeRP)

Secure eResearch Platform (SeRP)

Introduction

SeRP UK is operated as a private research cloud and is operated as a multi-tenancy model which means you control how and who uses it all under one pricing structure. It lets you build economies of scale and offers a cost effective data management and governance environment for users whilst also enabling them to be part of the SeRP UK research community. SeRP UK is accredited to the ISO27001 information security standard. SeRP UK is used by many research organisations across the UK to host research data within a secure research environment enabling collaborative research. SeRP UK is the perfect solution for any organisation that has accumulated a large amount of data, that intends to share that data for the purposes of research and long term benefit to society, and that wants to do so in the most secure and safe way possible to reduce associated risks.

Data Custodians (3)

Dementia Platform UK [OLD]
Datasets (0)Data Use (0)
Tools (0)Publications (0)
Collections (0)
BREATHE
Datasets (76)Data Use (0)
Tools (2)Publications (40)
Collections (13)
UK Longitudinal Linkage Collaboration (UK LLC)
Datasets (0)Data Use (0)
Tools (0)Publications (0)
Collections (0)

Datasets (76)

EMEP4UK Pollution
Dataset population size: Unknown
Health and disease
Asthma and COPD: practices and perceptions of GPs in rural India
Dataset population size: Unknown
Health and disease
4 Country ChrOnic Respiratory Disease study: PILOT PHASE, Islamabad
Dataset population size: 100
Health and disease
Genetics of Asthma Severity & Phenotypes
Dataset population size: Unknown
Health and disease
Optimum Patient Care Research Database
Dataset population size: Unknown
Health and disease

Analysis Scripts & Software (1)

Publications (40)

COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data.
Stock SJ, McAllister D, Vasileiou E, Simpson CR, Stagg HR, Agrawal U, McCowan C, Hopkins L, Donaghy J, Ritchie L, Robertson C, Sheikh A, Wood R.
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A, Salford Lung Study Investigators.
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A.
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A.
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators.
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, McCowan C, Agrawal U, Shah SA, Ritchie LD, Murray J, Pan J, Bradley DT, Stock SJ, Wood R, Chuter A, Beggs J, Stagg HR, Joy M, Tsang RSM, de Lusignan S, Hobbs R, Lyons RA, Torabi F, Bedston S, O'Leary M, Akbari A, McMenamin J, Robertson C, Sheikh A.